[Treatment of endometriosis with the GnRH analog triptorelin with special reference to the effect on bone density].

Zentralblatt fur Gynakologie · 1993 · vol. 115(11) , pp. 473–7 · PMID:8296491 · W2426130929
article OA: closed CC0 ⤵ 6 in-corpus citations
View on OpenAlex View on PubMed
AI-generated summary by claude@2026-06, 2026-06-07

Triptorelin treatment for endometriosis in 27 patients improved subjective symptoms and laparoscopic scoring without significant bone density loss or intolerable side effects.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

27 patients of the department of gynecology and obstetrics of the university of Essen received a six month therapy with the GnRH-analogon triptorelin because of endometriosis diagnosed by laparoscopy. All the patients experienced not only a significant improvement in their subjective symptoms but also in their rAFS-score which was used to classify the severity of the endometriosis of our patients. We could also show that no patient experienced any severe side effects under the therapy and those side effects such as hot flushes or sweating, which appeared, were almost tolerated very well by the patients. None of the patients did leave the study because of the side effects. We were also able to demonstrate that under the therapy there was no significant loss of the bone density. The introduction of the GnRH-analogon triptorelin is therefore a major step forward in the effective therapy of patients suffering from endometriosis.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Bone Density Endometriosis Triptorelin Pamoate Adult Bone Density Bone Density Dose-Response Relationship, Drug Drug Administration Schedule Endometriosis Endometriosis Endometriosis Estradiol Estradiol Female Follicle Stimulating Hormone Follicle Stimulating Hormone Humans Injections, Intramuscular Laparoscopy Luteinizing Hormone

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (6)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:11:44.647872+00:00
License: CC0 · commercial use OK